Comparison of the immune responses induced by Chimeric Alphavirus-Vectored and formalin-inactivated alum-precipitated measles vaccines in mice

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Bergen, M Jeff ^a,b,d   Pan, Chien Hsiung ^b,e   Greer, Catherine E ^c   Legg, Harold S ^c   Polo, John M ^c,f   Griffin, Diane E ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^f XOMA Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; FORMALDEHYDE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; INTERLEUKIN 4; MEASLES VACCINE; NEUTRALIZING ANTIBODY; NUCLEOPROTEIN; VIRUS HEMAGGLUTININ; VIRUS VECTOR; DNA VACCINE; HEMAGGLUTININ; IMMUNOGLOBULIN G; INACTIVATED VACCINE;

ALPHA VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; BONE MARROW; CHIMERA; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; GERMINAL CENTER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; LYMPH NODE; MEASLES; MEASLES VIRUS; MOUSE; NONHUMAN; REPLICON; SINGLE DRUG DOSE; T LYMPHOCYTE; VERO CELL; VIRUS NEUTRALIZATION; VIRUS PARTICLE; ANIMAL; ANTIBODY AFFINITY; BLOOD; COMPARATIVE STUDY; GENE VECTOR; GENETICS; HUMORAL IMMUNITY; IMMUNOLOGY; SERODIAGNOSIS;

ALPHAVIRUS; MEASLES VIRUS; MUS;

ALPHAVIRUS; ALUM COMPOUNDS; ANIMALS; ANTIBODY AFFINITY; FORMALDEHYDE; GENETIC VECTORS; HEMAGGLUTININS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; MEASLES VACCINE; MICE; NEUTRALIZATION TESTS; T-LYMPHOCYTES; VACCINES, DNA; VACCINES, INACTIVATED;

EID: 77956409183     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010297     Document Type: Article

References (98)

1. Moss WJ, Griffin DE (2006) Global measles elimination. Nat Rev Microbiol 4: 900-908.
2. Meissner HC, Strebel PM, Orenstein WA (2004) Measles vaccines and the potential for worldwide eradication of measles. Pediatrics 114: 1065-1069.
3. Orenstein WA, Strebel PM, Papania M, Sutter RW, Bellini WJ, et al. (2000) Measles eradication: is it in our future? Am J Public Health 90: 1521-1525.
4. Albrecht P, Ennis FA, Saltzman EJ, Krugman S (1977) Persistence of maternal antibody in infants beyond 12 months: Mechanism of measles vaccine failure. J Pediatr 91: 715-178.
5. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, et al. (1998) Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 280: 527-532.
6. Knudsen KM, Aaby P, Whittle H, Rowe M, Samb B, et al. (1996) Child mortality following standard, medium or high titre measles immunization in West Africa. Int J Epidemiol 25: 665-673.
7. Holt EA, Moulton LH, Siberry GK, Halsey NA (1993) Differential mortality by measles vaccine titer and sex. J Infect Dis 168: 1087-1096.
8. Low N, Kraemer S, Schneider M, Restrepo AM (2008) Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine 26: 383-398.
9. Pan CH, Jimenez GS, Nair N, Wei Q, Adams RJ, et al. (2008) Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. Clin Vaccine Immunol 15: 1214-1221.
10. Capozzo AV, Ramirez K, Polo JM, Ulmer J, Barry EM, et al. (2006) Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies. J Immunol 176: 5671-5681.
11. Pan CH, Valsamakis A, Colella T, Nair N, Adams RJ, et al. (2005) Inaugural Article: Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A 102: 11581-11588.
12. Pasetti MF, Barry EM, Losonsky G, Singh M, Medina-Moreno SM, et al. (2003) Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats. J Virol 77: 5209-5217.
13. Song MK, Vindurampulle CJ, Capozzo AV, Ulmer J, Polo JM, et al. (2005) Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins. J Virol 79: 9854-9861.
14. Polack F, Lee S, Permar S, Manyara E, Nousari H, et al. (2000) Successful DNA immunization against measles: Neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat Med 6: 776-781.
15. Enders JF, Peebles TC (1954) Propagation in tissue cultures of cytopathic agents from patients with measles. Proc Soc Exp Biol Med 86: 277-286.
16. Griffin DE, Pan C-H (2009) Measles: Old vaccines, new vaccines. Curr Top Microbiol Immunol 330: 191-212.
17. Enders JF, Katz SL, Holloway A (1962) Development of attenuated measles-virus vaccines. Am J Dis Child 103: 335-340.
18. Katz SL, Enders JF, Holloway A (1962) The development and evaluation of an attenuated measles virus vaccine. Am J Public Health Nations Health 52 Suppl: 5-10.
19. Warren J, Gallian MJ (1962) Concentrated inactivated measles-virus vaccine: Preparation and antigenic potency. Amer J Dis Child 103: 248-253.
20. Feldman HA (1962) Protective value of inactivated measles vaccine. Am J Dis Child 103: 423-424.
21. Warren J, Crawford JG, Gallian MJ (1962) Potency measurement of inactivated measles vaccines. Am J Dis Child 103: 452-457.
22. Carter CH, Conway TJ, Cornfeld D, Iezzoni DG, Kempe CH, et al. (1962) Serologic response of children to inactivated measles vaccine. JAMA 179: 848-853.
23. Rauh LW, Schmidt R (1965) Measles immunization with killed virus vaccine. Amer J Dis Child 109: 232-237.
24. Fulginiti VA, Arthur JH (1969) Altered reactivity to measles virus. Skin test reactivity and antibody response to measles virus antigens in recipients of killed measles virus vaccine. J Pediatr 75: 609-616.
25. Fulginiti VA, Eller JJ, Downie AW, Kempe CH (1967) Altered reactivity to measles virus: Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 202: 1075-1080.
26. Annunziato D, Kaplan MH, Hall WW, Ichinose H, Lin JH, et al. (1982) Atypical measles syndrome: Pathologic and serologic findings. Pediatrics 70: 203-209.
27. Nichols EM (1979) Atypical measles syndrome: a continuing problem. Am J Public Health 69: 160-162.
28. McLean DM, Kettylis GDM, Hingston J, Moore PS, Paris RP, et al. (1970) Atypical measles following immunization with killed measles vaccine. Can Med Assoc J 103: 743-744.
29. Gokiert JG, Beamish WE (1970) Altered reactivity to measles virus in previously vaccinated children. Can Med Assoc J 103: 724-727.
30. Brodsky AL (1972) Atypical measles. Severe illness in recipients of killed measles virus vaccine upon exposure to natural infection. JAMA 222: 1415-1416.
31. Martin DB, Weiner LB, Nieburg PI, Blair DC (1979) Atypical measles in adolescents and young adults. Ann Int Med 90: 877-881.
32. Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R, et al. (2006) A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 12: 905-907.
33. Polack FP, Auwaerter PG, Lee S-H, Nousari HC, Valsamakis A, et al. (1999) Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat Med 5: 629-634.
34. Polack FP, Hoffman SJ, Crujeiras G, Griffin DE (2003) A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med 9: 1209-1213.
35. Amanna IJ, Carlson NE, Slifka MK (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357: 1903-1915.
36. Graves MC, Griffin DE, Johnson RT, Hirsch RL, Lindo de Soriano I, et al. (1984) Development of antibody to measles virus polypeptides during complicated and uncomplicated measles virus infections. J Virol 49: 409-412.
37. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, et al. (1990) Measles antibody: reevaluation of protective titers. J Infect Dis 162: 1036-1042.
38. Bouche FB, Ertl OT, Muller CP (2002) Neutralizing B cell response in measles. Viral Immunol 15: 451-471.
39. Malvoisin E, Wild F (1990) Contribution of measles virus fusion protein in protective immunity: anti-F monoclonal antibodies neutralize virus infectivity and protect mice against challenge. J Virol 64: 5160-5162.
40. Merz DC, Scheid A, Choppin PW (1980) Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection. J Exp Med 151: 275-288.
41. de Swart RL, Yuksel S, Osterhaus AD (2005) Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization. J Virol 79: 11547-11551.
42. Ertl OT, Wenz DC, Bouche FB, Berbers GA, Muller CP (2003) Immunodo-minant domains of the measles virus hemagglutinin protein eliciting a neutralizing human B cell response. Arch Virol 148: 2195-2206.
43. Rayner JO, Dryga SA, Kamrud KI (2002) Alphavirus vectors and vaccination. Rev Med Virol 12: 279-296.
44. Strauss JH, Strauss EG (1994) The alphaviruses: Gene expression, replication and evolution. Microbiol Rev 58: 491-562.
45. Liljestrom P, Garoff H (1991) A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Bio/Tech 9: 1356-1361.
46. Bredenbeek PJ, Frolov I, Rice CM, Schlesinger S (1993) Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J Virol 67: 6439-6446.
47. Polo JM, Belli B, Driver D, Frolov I, Sherrill S, et al. (1999) Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc Natl Acad Sci USA 96: 4598-4603.
48. Perri S, Greer CE, Thudium K, Doe B, Legg H, et al. (2003) An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 77: 10394-10403.
49. Greer CE, Zhou F, Legg HS, Tang Z, Perri S, et al. (2007) A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge. Vaccine 25: 481-489.
50. Mok H, Tollefson SJ, Podsiad AB, Shepherd BE, Polosukhin VV, et al. (2008) An alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats. J Virol 82: 11410-11418.
51. White LJ, Parsons MM, Whitmore AC, Williams BM, de Silva A, et al. (2007) An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice. J Virol 81: 10329-10339.
52. Thompson JM, Whitmore AC, Konopka JL, Collier ML, Richmond EM, et al. (2006) Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc Natl Acad Sci USA 103: 3722-3727.
53. Leitner WW, Hwang LN, deVeer MJ, Zhou A, Silverman RH, et al. (2003) Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 9: 33-39.
54. Thompson JM, Nicholson MG, Whitmore AC, Zamora M, West A, et al. (2008) Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node. J Immunol 181: 574-585.
55. Pan C-H, Greer CE, Hauer D, Legg HS, Lee E-Y, et al. (2010) A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J Virol In press.
56. Pan CH, Nair N, Adams RJ, Zink MC, Lee EY, et al. (2008) Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques. Clin Vaccine Immunol 15: 697-706.
57. Etchart N, Buckland R, Liu MA, Wild TF, Kaiserlian D (1997) Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin. J Gen Virol 78: 1577-1580.
58. Webster DE, Cooney ML, Huang Z, Drew DR, Ramshaw IA, et al. (2002) Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine. J Virol 76: 7910-7912.
59. Stittelaar KJ, Boes J, Kersten GF, Spiekstra A, Mulder PG, et al. (2000) In vivo antibody response and in vitro CTL activation induced by selected measles vaccine candidates, prepared with purified Quil A components. Vaccine 18: 2482-2493.
60. Chabot S, Brewer A, Lowell G, Plante M, Cyr S, et al. (2005) A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice. Vaccine 23: 1374-1383.
61. Kraal G, Weissman IL, Butcher EC (1982) Germinal centre B cells: antigen specificity and changes in heavy chain class expression. Nature 298: 377-379.
62. Shinall SM, Gonzalez-Fernandez M, Noelle RJ, Waldschmidt TJ (2000) Identification of murine germinal center B cell subsets defined by the expression of surface isotypes and differentiation antigens. J Immunol 164: 5729-5738.
63. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, et al. (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6: 741-750.
64. Slifka MK, Matloubian M, Ahmed R (1995) Bone marrow is a major site of long-term antibody production after acute viral infection. J Virol 69: 1895-1902.
65. Rivailler P, Trescol-Biemont M-C, Gimenez C, Rabourdin-Combe C, Horvath B (1998) Enhanced MHC class II-restricted presentation of measles virus (MV) hemagglutinin in transgenic mice expressing human MV receptor CD46. Eur J Immunol 28: 1301-1314.
66. van Els CA, Nanan R (2002) T cell responses in acute measles. Viral Immunol 15: 435-450.
67. Halassy B, Mateljak S, Bouche FB, Putz MM, Muller CP, et al. (2006) Immunogenicity of peptides of measles virus origin and influence of adjuvants. Vaccine 24: 185-194.
68. Muller CP, Bunder R, Mayser H, Ammon S, Weinmann M, et al. (1995) Intramolecular immunodominance and intermolecular selection of H2d-restricted peptides define the same immunodominant region of the measles virus fusion protein. Mol Immunol 32: 37-47.
69. Fournier P, Ammerlaan W, Ziegler D, Giminez C, Rabourdin-Combe C, et al. (1996) Differential activation of T cells by antibody-modulated processing of the flanking sequences of class II-restricted peptides. Int Immunol 8: 1441-1451.
70. Fahrer AM, Geysen HM, White DO, Jackson DC, Brown LE (1995) Analysis of the requirements for class II-restricted T cell recognition of a single determinant reveals considerable diversity in the T cell response and degeneracy of peptide binding to I-Ed. J Immunol 155: 2849-2857.
71. Manz RA, Arce S, Cassese G, Hauser AE, Hiepe F, et al. (2002) Humoral immunity and long-lived plasma cells. Curr Opin Immunol 14: 517-521.
72. DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, et al. (2008) Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 180: 361-371.
73. Slifka MK, Antia R, Whitmire JK, Ahmed R (1998) Humoral immunity due to long-lived plasma cells. Immunity 8: 363-372.
74. Benner R, Meima F, van der Meulen GM, van Muiswinkel WB (1974) Antibody formation in mouse bone marrow. I. Evidence for the development of plaque-forming cells in situ. Immunology 26: 247-255.
75. Hofer T, Muehlinghaus G, Moser K, Yoshida T, Mei E, et al. (2006) Adaptation of humoral memory. Immunol Rev 211: 295-302.
76. Bourhis JM, Receveur-Brechot V, Oglesbee M, Zhang X, Buccellato M, et al. (2005) The intrinsically disordered C-terminal domain of the measles virus nucleoprotein interacts with the C-terminal domain of the phosphoprotein via two distinct sites and remains predominantly unfolded. Protein Sci 14: 1975-1992.
77. Fox CH, Johnson FB, Whiting J, Roller PP (1985) Formaldehyde fixation. J Histochem Cytochem 33: 845-853.
78. Norrby E, Enders-Ruckle G, ter Meulen V (1975) Differences in the appearance of antibodies to structural components of measles virus after immunization with inactivated and live virus. J Infect Dis 132: 262-269.
79. Marrack P, McKee AS, Munks MW (2009) Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9: 287-293.
80. Lindblad EB (2004) Aluminium compounds for use in vaccines. Immunol Cell Biol 82: 497-505.
81. Grun JL, Maurer PH (1989) Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol 121: 134-145.
82. Gardner J, Frolov I, Perri S, Ji Y, MacKichan M, et al. (2000) Infection of human dendritic cells by a Sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J Virol 74: 11849-11857.
83. Leitner WW, Bergmann-Leitner ES, Hwang LN, Restifo NP (2006) Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine 24: 5110-5118.
84. Konopka JL, Penalva LO, Thompson JM, White LJ, Beard CW, et al. (2007) A two-phase innate host response to alphavirus infection identified by mRNP-tagging in vivo. PLoS Pathog 3: e199.
85. Thompson JM, Whitmore AC, Staats HF, Johnston R (2008) The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine 26: 4998-5003.
86. Chen M, Hu KF, Rozell B, Orvell C, Morein B, et al. (2002) Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J Immunol 169: 3208-3216.
87. Mok H, Lee S, Utley TJ, Shepherd BE, Polosukhin VV, et al. (2007) Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol 81: 13710-13722.
88. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, et al. (2000) Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102: 553-563.
89. Malherbe L, Mark L, Fazilleau N, Heyzer-Williams LJ, Heyzer-Williams MG (2008) Vaccine adjuvants alter TCR-based selection thresholds. Immunity 28: 698-709.
90. McKee AS, Munks MW, Marrack P (2007) How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27: 687-690.
91. Kolla RV, Chintalapati S, Sabet M, Santelli E, Liddington RC, et al. (2007) Complement C3d conjugation to anthrax protective antigen promotes a rapid, sustained, and protective antibody response. PLoS One 2: e1044.
92. Kelsoe G (1996) The germinal center: a crucible for lymphocyte selection. Semin Immunol 8: 179-184.
93. Bachmann MF, Odermatt B, Hengartner H, Zinkernagel RM (1996) Induction of long-lived germinal centers associated with persisting antigen after viral infection. J Exp Med 183: 2259-2269.
94. MacLennan IC, Toellner KM, Cunningham AF, Serre K, Sze DM (2003) Extrafollicular antibody responses. Immunol Rev 194: 8-18.
95. Beauverger P, Buckland R, Wild F (1993) Establishment and characterisation of murine cells constitutively expressing the fusion, nucleoprotein and matrix proteins of measles virus. J Virol Meth 44: 199-210.
96. Nair N, Gans H, Lew-Yasukawa L, Long-Wagar AC, Arvin A, Griffin DE (2007) Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis 196: 1339-1345.
97. Pullen GR, Fitzgerald MG, Hosking CS (1986) Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Meth 86: 83-87.
98. Auwaerter PG, Rota PA, Elkins WR, Adams RJ, DeLozier T, et al. (1999) Measles virus infection in rhesus macaques: Altered immune responses and comparison of the virulence of six different virus strains. J Infect Dis 180: 950-958.